CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 5,940 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01078558
NCT01078558N/ACompleted
CompareCT.gov

A Five Year, Post-marketing Observational Study to Follow-up Patients With Rheumatoid Arthritis or Psoriatic Arthritis Who Are Treated With HUMIRA (Adalimumab)

AbbVie (prior sponsor, Abbott)·observational·Posted Mar 2, 2010·Updated Jul 5, 2019

In Brief

An observational study for Rheumatoid Arthritis and 2 related conditions. Completed, enrolled 5,940 participants.

Detailed Summary

This is a five year, post-marketing observational study to follow-up patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis who are treated with HUMIRA (adalimumab).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis
Countries--
CollaboratorsVeeda Clinical Research

Timeline

N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2, 2010
Enrollment StartMay 13, 2004
Primary CompletionJan 11, 2018
TodayJul 2, 2026
Enrollment to primary: 13.7 yearsPosted 16.3 years ago